{"id":57044,"date":"2026-04-28T14:17:12","date_gmt":"2026-04-28T14:17:12","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/57044\/"},"modified":"2026-04-28T14:17:12","modified_gmt":"2026-04-28T14:17:12","slug":"novartis-boehringer-eli-lilly-erasca-readout-newsletter","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/57044\/","title":{"rendered":"Novartis, Boehringer, Eli Lilly, Erasca: Readout Newsletter"},"content":{"rendered":"

Want to stay on top of the science and politics driving biotech today?\u00a0Sign up<\/a>\u00a0to get our biotech newsletter in your inbox.<\/p>\n

Good morning. I started the\u00a0morning reading this story<\/a> of how a botched football kick may have saved someone\u2019s life.<\/p>\n

The need-to-know this morning<\/p>\n

Novartis shares were down in early trading after the company reported a drop in sales and operating profit<\/a> in the first quarter, with generic competition hitting drugs like Entresto hard. The company affirmed its guidance for the year, with net sales expected to grow in the low single digits, and core operating profit forecasted to decline slightly.<\/p>\n

The FDA has taken further actions to withdraw the approval<\/a> of Amgen\u2019s rare-disease drug Tavneos and remove it from the market. Tavneos was approved in 2021, but new information indicates the drug is ineffective and the application used to support approval contained \u201cuntrue statements of material fact,\u201d the FDA said. Amgen has refused to withdraw <\/a>Tavneos voluntarily, insisting the drug is safe.<\/p>\n

Lilly bets on next-gen gene editors with new deal<\/p>\n

Eli Lilly this morning announced a deal with AI-focused biotech Profluent to develop new forms of\u00a0gene editors potentially capable of inserting entire genes into patients.<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\t\t\t\t\t\t\"STAT+\"\/<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Want to stay on top of the science and politics driving biotech today?\u00a0Sign up\u00a0to get our biotech newsletter…\n","protected":false},"author":2,"featured_media":57045,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[336,324,1000,206,338],"class_list":{"0":"post-57044","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novartis","8":"tag-biotechnology","9":"tag-drug-development","10":"tag-drug-prices","11":"tag-novartis","12":"tag-research"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116482765275021554","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/57044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=57044"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/57044\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/57045"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=57044"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=57044"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=57044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}